With the acquisition by Novartis offering a tender of $7 per share plus contingent value rights, I believe RGLS has potential for further growth, especially if the necessary regulatory milestones are met. Even after the spike, I see value in holding until the completion of the merger.

Given the positive top-line data from Regulus Therapeutics' recent kidney disease study and the bullish sentiment from analysts, I believe RGLS is positioned for significant growth. This strong clinical data indicates a promising outlook, making it an attractive long-term investment opportunity.